Avrobio, Inc. (AVRO) SEC Filing 8-K Material Event for the period ending Tuesday, May 17, 2022

Avrobio, Inc.

CIK: 1681087 Ticker: AVRO

View differences made from one to another to evaluate Avrobio, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Avrobio, Inc..


Assess how Avrobio, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Avrobio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Avrobio, Inc. provided additional information to their SEC Filing as exhibits

Ticker: AVRO
CIK: 1681087
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-152426
Submitted to the SEC: Tue May 17 2022 7:12:07 AM EST
Accepted by the SEC: Tue May 17 2022
Period: Tuesday, May 17, 2022
Industry: Biological Products No Disgnostic Substances
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: